Home › Uterine Fibroids › NCT06705075

Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE

Evaluation of Uterine Fibroids by Contrast Enhanced Ultrasound (CEUS) and Subharmonic- Aided Pressure Estimation (SHAPE) Pre and Post-Uterine Artery Embolization (UAE)

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Be a female diagnosed with endometrial cancer and scheduled for UAE.
* Be over the age of 18 years.
* If the subject is of child-bearing potential, must have a negative pregnancy test.
* Be conscious and able to comply with study procedures.
* Have read and signed the IRB approved consent form for participating in the study.

Exclusion Criteria:

* Females who are pregnant or nursing.
* Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards.
* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
* Patients on life support or in a critical care unit.
* Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.
* Patients with recent cerebral hemorrhage.
* Patients who have undergone surgery within 24 hours prior to the study sonographic examination.
* Patients with congenital heart defects.
* Patient with a known allergy to Definity.

About the study

This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.

What is being tested

• Perfluten (drug)

Sponsor: Thomas Jefferson University · Participants: 80 · Started: Jan 27, 2025

Contact the study team

• Priscilla Machado, MD · Phone: 215-955-4279

Official record on ClinicalTrials.gov — NCT06705075

Locations in the U.S.

Conditions

• Uterine Fibroids

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.